Bluebird bio, Inc. Announces Departure of Mitchell H. Finer as Chief Scientific Officer, Effective of July 06, 2015
January 29, 2015 at 04:21 pm EST
Share
bluebird bio, Inc. announced that Mitchell H. Finer, Ph.D., chief scientific officer, has decided to transition from his current role with bluebird bio over the next six months. At the end of this transition period, he will remain an important scientific voice at bluebird bio by serving on the company's scientific advisory board and continuing to share his experience and insights to benefit the company's scientific strategy. The company is now initiating the process of recruiting for a CSO replacement.
bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. Its lead gene therapy programs for sickle cell disease, B-thalassemia, and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. It has two gene therapies: ZYNTEGLO (betibeglogene autotemcel) and SKYSONA (elivaldogene autotemcel). ZYNTEGLO is the first gene therapy for people with B-thalassemia who require regular red blood cell transfusions. SKYSONA (elivaldogene autotemcel), also known as eli-cel, is used to slow the progression of eurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). It is also developing (lovotibeglogene autotemcel), also known as lovo-cel, as a one-time treatment for patients with sickle cell disease (SCD).
BLUEBIRD BIO, INC. 
